Envista Holdings Corporation
NYSE•NVST
CEO: Mr. Stephen Keller
Sector: Healthcare
Industry: Medical - Equipment & Services
Listing Date: 2019-09-18
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Contact Information
Building E, 200 South Kraemer Boulevard, Brea, CA, 92821-6208, United States
714-817-7000
Market Cap
$4.67B
P/E (TTM)
99.4
37.1
Dividend Yield
--
52W High
$30.42
52W Low
$14.22
52W Range
Rank40Top 42.0%
4.1
F-Score
Modified Piotroski Analysis
Based on 9-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2025
Financial Dashboard
Q4 2025 Data
Revenue
$750.60M+0.00%
4-Quarter Trend
EPS
$0.20+0.00%
4-Quarter Trend
FCF
$91.70M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Total sales reached $2.72B USD in 2025, reflecting a strong 8.3% GAAP growth compared to the prior year.
Profitability Rebound Net income was $47.0M USD, successfully reversing the substantial $1.12B net loss recorded in 2024 operations.
Impairment Absence Zero goodwill impairment recorded in 2025 versus $1.15B goodwill and intangible asset charge recognized in 2024.
Core Sales Strength Core sales grew 6.5% USD, driven by Specialty Products segment achieving 6.3% growth for the fiscal year.
Risk Factors
Global Economic Volatility Global economy, inflation, and interest rates may adversely affect customer demand and utilization rates across served markets.
Trade Policy Uncertainty Trade disputes, tariffs, and protectionism increase sourcing costs and restrict market access across international operations.
Cybersecurity Incident Risk IT system breaches or ransomware attacks could seriously harm operations, cause data loss, and result in reputational damage.
Distributor Concentration Loss of key distributor Henry Schein, accounting for 12% of 2025 sales, poses a material concentration risk to revenue streams.
Outlook
Strategic Growth Investment Investing in innovation, commercialization, and clinical education remains a key priority to accelerate overall business growth trajectory.
Emerging Market Focus Continue investing in emerging markets, which represented 22% of 2025 total sales volume, expecting strong future growth driver.
Operational Efficiency Focus Utilizing Envista Business System (EBS) to improve manufacturing performance and streamline overall operational cost structure.
Recent Acquisition Integration Completed Versah acquisition for approximately $55.0M cash in February 2026 to expand portfolio with innovative dental technology.
Peer Comparison
Revenue (TTM)
$3.95B
$3.68B
$2.72B
Gross Margin (Latest Quarter)
92.2%
89.1%
86.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TMDX | $5.05B | 26.6 | 53.9% | 44.0% |
| CGON | $4.97B | -29.6 | -22.9% | 0.9% |
| NVST | $4.67B | 99.4 | 1.5% | 30.1% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.8%
Steady Growth
4Q Net Income CAGR
22.3%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data